Nurix Therapeutics, Inc.
NRIX · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -82.1% | 138.7% | 38.9% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 36.7% | -77.3% | -277.5% | -406.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,031.4% | -104.6% | -327.9% | -477.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,094.8% | -98.7% | -305.4% | -440.7% |
| EPS Diluted | -1.03 | -0.52 | -0.67 | -0.75 |
| % Growth | -98.1% | 22.4% | 10.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |